Ligand Pharmaceuticals reported $20.18M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Amgen USD 1.69B 4M Jun/2025
Arrowhead Research USD 30.95M 3.06M Jun/2025
Baxter International USD 718M 15M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
Insmed USD 76.44M 71.11M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
Ligand Pharmaceuticals USD 20.18M 1.37M Jun/2025
MacroGenics USD 9.3M 18.51M Jun/2025
Merck USD 2.63B 104M Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Veracyte USD 57.65M 1.51M Jun/2025